Takeda Pharmaceutical Co Ltd
TKDA
Company Profile
Business description
Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Contact
1-1, Nihonbashi-Honcho 2-Chome
Chuo-ku
Tokyo103-8668
JPNT: +81 332782306
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
47,455
Stocks News & Analysis
stocks
Overpriced ASX listed consumer electronics retailers
Solid balance sheets, lower business risk and strong sales but investors are overly optimistic.
stocks
Nvidia and AMD: Maintain fair value estimate amid reports of Meta’s negotiations to buy Google TPUs
Our update on select stocks from the Semiconductors industry.
stocks
Alphabet: Gemini momentum and possible Meta TPU deal underscore AI capability
We think Alphabet is exceptionally well positioned in everything AI.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,899.30 | 6.50 | -0.07% |
| CAC 40 | 8,096.43 | 70.63 | 0.88% |
| DAX 40 | 23,726.22 | 261.59 | 1.11% |
| Dow JONES (US) | 47,507.04 | 394.59 | 0.84% |
| FTSE 100 | 9,691.58 | 82.05 | 0.85% |
| HKSE | 25,928.08 | 33.53 | 0.13% |
| NASDAQ | 23,256.35 | 230.76 | 1.00% |
| Nikkei 225 | 49,559.07 | 899.55 | 1.85% |
| NZX 50 Index | 13,562.01 | 81.58 | 0.61% |
| S&P 500 | 6,826.77 | 60.89 | 0.90% |
| S&P/ASX 200 | 8,606.50 | 9.50 | -0.11% |
| SSE Composite Index | 3,864.18 | 5.84 | -0.15% |